Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, Lodz, Poland.
Department of Gastroenterology, Medical University, Lodz, Poland.
Biomed Res Int. 2017;2017:3204504. doi: 10.1155/2017/3204504. Epub 2017 May 29.
Taking statins can cause increase in the level of aspartate and alanine aminotransferase. The aim of this study was to assess the usefulness of melatonin in counteracting the adverse hepatic events from statins. . The research program included 60 patients (aged 47-65 years, 41 women and 19 men) with hyperlipidemia taking atorvastatin or rosuvastatin at a dose of 20-40 mg daily. The patients were randomly allocated in two groups. Group I ( = 30) was recommended to take the same statin at a standardized daily dose of 20 mg together with melatonin at a dose of 2 × 5 mg. Group II ( = 30) patients took statin with placebo at the same dose and time of the day. Follow-up laboratory tests (AST, ALT, GGT, and ALP) were evaluated after 2, 4, and 6 months of treatment. . In Group I the levels of all enzymes decreased after 6 months, particularly AST, 97,2 ± 19,1 U/L versus 52,8 ± 12,3 U/L ( < 0,001); ALT, 87,4 ± 15,6 U/L versus 49,8 ± 14,5 U/L ( < 0,001); and GGT, 84,1 ± 14,8 U/L versus 59,6 U/L ( < 0,001). . Melatonin exerts a hepatoprotective effect in patients taking statins.
服用他汀类药物会导致天门冬氨酸氨基转移酶和丙氨酸氨基转移酶水平升高。本研究旨在评估褪黑素在对抗他汀类药物的肝不良事件方面的作用。该研究方案纳入了 60 名（年龄 47-65 岁，女性 41 名，男性 19 名）服用阿托伐他汀或瑞舒伐他汀（剂量为 20-40mg/d）的高血脂患者。患者被随机分为两组。I 组（n=30）被建议在每日标准化剂量 20mg 的他汀类药物基础上加用 2×5mg 的褪黑素。II 组（n=30）患者在相同剂量和时间服用安慰剂。治疗 2、4 和 6 个月后，评估实验室检测的（AST、ALT、GGT 和 ALP）结果。结果：I 组患者在 6 个月后所有酶水平均降低，尤其是 AST（97.2±19.1U/L 比 52.8±12.3U/L，<0.001）；ALT（87.4±15.6U/L 比 49.8±14.5U/L，<0.001）；GGT（84.1±14.8U/L 比 59.6U/L，<0.001）。结论：褪黑素对服用他汀类药物的患者具有肝脏保护作用。
